Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.64 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | CHRNG | P07510 | 1/20 | 0.64 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.64 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | HTR3A | P46098 | 1/20 | 0.64 |
| ▸ | CHRND | Q07001 | 1/20 | 0.64 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761231 | 1.00 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL23153171 | 0.82 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL14117078 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL13285194 | 0.82 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074660 | 0.81 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074656 | 0.80 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL21074782 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL18117455 | 0.78 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL15003906 | 0.78 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL16343697 | 0.78 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | claimed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| EP-4241775-A1 | TABLET COMPRISING VARENICLINE AND PROCESS OF PREPARATION THEREOF | Par Pharmaceutical, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2013-04-25 | — | — | US | disclosed |
| WO-2011110954-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-20130101630-A1 | HIGHLY PURE VARENICLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF METHYLVARENICLINE IMPURITY | PDE7A, CHRNA7, HTR7 | CHRNB2 52/4885CHRNA4 48/4885CHRNB4 102/4885 |
| US-11779587-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20230285406-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.